Roivant publishes mosliciguat PHocus trial topline results presentation

• Roivant published a presentation on topline results from the Phase 2 PHocus study of inhaled mosliciguat in PH-ILD.
• Primary endpoint met, with a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16 (p<0.0001).
• Key secondary endpoint showed a 35.2 m placebo-adjusted gain in 6-minute walk distance at Week 16 (p=0.0027).
• Week 24 updates included a 75.9% placebo-adjusted NT-proBNP reduction (p<0.0001) and a 52.7 m 6-minute walk distance gain (p<0.0001).
• Phase 3 PHrontier program in PH-ILD initiated; cough incidence was 12.1% on mosliciguat versus 18.2% on placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.